The city's top power players within Houston's energy innovation ecosystem joined virtual SXSW to discuss Houston's life science innovation scene and developing an inclusive ecosystem. Photos courtesy

Another day of SXSW 2021 has concluded, and just like the first day, Houston innovators logged on to discuss technology and innovation that's taking off in town.

The second of the two days of programming focused on the development of the Houston innovation ecosystem — including how the city is factoring in diversity and inclusion into development — with interviews hosted by me, Natalie Harms, editor of InnovationMap. Missed out on the fun? Catch up with a few overheard moments from Houston House or stream the full interviews below.

"“We have to be true to ourselves of what works for Houston. Making sure the DEI is interwoven and in our DNA of our ecosystem so that we don’t make the same mistakes as other cities." — Ashley DeWalt, managing director of DivInc Houston

Video courtesy of the Greater Houston Partnership

Houston has an advantage in developing its innovation ecosystem because it can do so by learning from established ecosystems on the coasts. Locally, that means making diversity and inclusion a top priority. At a virtual SXSW Houston House panel, Ashley DeWalt, managing director of DivInc Houston, and Jan Odegard, interim executive director of The Ion, discuss the importance of prioritizing inclusion in developing Houston's innovation ecosystem. Click here to watch the full interview.

“This pandemic has really highlighted a lot of the health care disparities that are present within our systems. … Houston is in a unique position to address that.” — Fiona Mack, head of JLABS @ TMC

Video courtesy of the Greater Houston Partnership

The Texas Medical Center is the largest medical center in the world with over 10 million patients coming in annually — and JLABS @ TMC is right in the middle of that. With this access to patients and clinical trials, Houston has a lot of potential to attract new innovative companies solving the world's biggest health care problems. At a virtual SXSW Houston House HOU Talk, Fiona Mack, head of JLABS @TMC, discusses the momentum behind health tech innovation in Houston. Click here to watch the full interview.

“Whatever the training is, you have to actually create bias disruptors and points of friction and processes that change behavior. If we don’t have a way to implement what we learn, it doesn’t really change culture.” — LaTanya Flix, senior vice president at the GHP

Video courtesy of the Greater Houston Partnership

In light of the Black Lives Matter movement, corporations of all shapes and sizes were inspired to look inward to address inequity within their workforce — from training to shifts in workplace culture. At a virtual SXSW Houston House HOU Talk, LaTanya Flix, senior vice president of Diversity, Equity and Inclusion (DEI) at the Greater Houston Partnership, shares how she's on a mission to spread mindful DEI initiatives across all of the GHP's member organizations. Click here to watch the full interview.

“I see a world where I’m sitting in a boardroom, and I’m not the only woman anymore.” — Samantha Lewis, principal at Mercury Fund

Video courtesy of the Greater Houston Partnership

Women in venture capital are used to being the only women in the room and are fighting for that not to be the case for future generations. At a virtual SXSW Houston House panel, Sandy Guitar, managing director of the HX Venture Fund moderates a discussion with fellow women in VC, Paige Pitcher, director of innovation at Hines, and Samantha Lewis, principal at Mercury Fund. Click here to watch the full interview.

“There’s an incredible number of innovations that have popped up in Houston, but a lot of them have been centered around solving engineering-type problems at industrial scale — and that still exists, but doesn’t get as much coverage as consumer-facing technologies.” — Josh Pherigo, director of research and data analytics at GHP

Video courtesy of the Greater Houston Partnership

When tracking any sort of progress or growth, business look to their numbers and data. Houston's innovation system is no different. At a virtual SXSW Houston House HOU Talk, Josh Pherigo, director of research and data analytics at the Greater Houston Partnership, dives in deep with the facts and figures of Houston's burgeoning innovation ecosystem by following the venture dollars coming into local startups. Click here to watch the full interview.

“If you look at the density in Houston, being the energy capital of the United States, there are probably few places in the world where you can walk 15 minutes in either direction and talk to about 100 companies that would potentially be customers.” — Matthew Costello, CEO and co-founder of Voyager Portal

Video courtesy of the Greater Houston Partnership

A good startup idea comes from necessity and a way to apply technology to solve problems and shorten business delivery times, and the maritime shipping industry has a lot of opportunities for these types of innovations. At a virtual SXSW Houston House HOU Talk, Matthew Costello, CEO and co-founder of Voyager Portal, sets sail on a conversation about the maritime shipping industry — and how it was ripe with disruption. Click here to watch the full interview.

“You have institutions of exception in Houston where innovation flows from. The question isn’t that it’s not there, it’s how have we been tapping it.” — David Schubert, president of Magnolia Tejas Corp.

Video courtesy of the Greater Houston Partnership

Houston has a burgeoning life science innovation scene — but what's that next step for its development? At a virtual SXSW Houston House HOU Talk, David Schubert, president of Magnolia Tejas Corp. discusses the potential of Houston's world-class oncologists and biotech innovators have to make the city a hub for cancer innovation. Click here to watch the full interview.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.